Tue.Nov 28, 2023

article thumbnail

Pharma benefited from basing business overseas. An international tax effort could spur a rethink.

Bio Pharma Dive

U.S. tax law changes enacted six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.

article thumbnail

FDA accepts Orexo’s NDA for opioid overdose medication

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has accepted to review Orexo’s new drug application (NDA) for opioid overdose medication, OX124.

Drugs 263
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA investigating cancer risk linked to CAR-T cell therapy

Bio Pharma Dive

The agency said the benefit of approved treatments like Gilead’s Yescarta still outweighs any such risk, but the alert could slow drugmaker efforts to develop the treatments for wider use.

article thumbnail

Novovax’s Omicron-targeting Covid-19 vaccine obtains WHO emergency listing  

Pharmaceutical Technology

The emergency use listing is based on non-clinical data where the vaccine demonstrated immune responses against variants in SARS-CoV-2.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Roivant’s Matt Gline on raising capital and biotech’s outlook in 2024

Bio Pharma Dive

Fresh off a $7 billion deal with Roche, the chief executive spoke with BioPharma Dive about this year’s “discordant combination” of major biotech achievements alongside market headwinds.

Marketing 195
article thumbnail

Radiopharmaceuticals reach record high with $408m in venture financing for 2023

Pharmaceutical Technology

Venture financing for innovative radiopharmaceutical drugs witnessed an approximately 550% increase from $63m in 2017 to $408m in 2023 YTD (year-to-date) total deal value in the US.

Drugs 246

More Trending

article thumbnail

Acelyrin claims errors by CRO Fortrea led to late-stage trial downfall

Pharmaceutical Technology

A Phase IIb/III trial studying the company’s immunotherapy izokibep, failed to achieve statistical significance for its primary endpoint

Trials 246
article thumbnail

Novartis sees brighter sales future as R&D revamp continues

Bio Pharma Dive

The pharma has overhauled its pipeline this year, cutting R&D programs outside of its four main therapeutic areas.

Sales 162
article thumbnail

Emergent wins $75m BARDA contact for anthrax vaccine

Pharmaceutical Technology

Emergent’s Cyfendus was approved by the US FDA as a post-exposure prophylactic vaccine for anthrax in July.

article thumbnail

November 28, 2023: Workshop Summary Now Available From ‘Getting the Right Evidence to Decision-Makers Faster’

Rethinking Clinical Trials

The workshop summary is now available from the NIH Pragmatic Trials Collaboratory’s recent workshop, “Getting the Right Evidence to Decision-Makers Faster.” The 2-day workshop explored the critical cycle of evidence generation by researchers to decision-making by healthcare system leaders to implement the findings of pragmatic clinical trials conducted within healthcare systems.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

FDA rejects Aldeyra’s dry eye drug, asks for more clinical data

Pharmaceutical Technology

Aldeyra has submitted new trial plans to the US FDA, and anticipates NDA resubmission for reproxalap in H1 2024.

Drugs 147
article thumbnail

FDA investigates 'serious risk' of secondary cancer following CAR-T treatment

Fierce Pharma

In a blow to CAR-T therapies, the FDA is investigating a “serious risk” of patients developing new cancers after treatment with these highly efficacious oncology drugs. | In a blow to CAR-T therapies, the FDA is investigating a “serious risk” of patients developing new cancers after treatment with these highly efficacious oncology drugs.

article thumbnail

Abeona’s cell therapy secures priority approval date for rare skin disorder

Pharmaceutical Technology

The agency has set a PDUFA date of 25 May 2024 for pz-cel, which if approved, Abeona would be eligible for a priority review voucher.

147
147
article thumbnail

Pfizer takes Poland to court over alleged missed COVID-19 vaccine payments

Fierce Pharma

As the pandemic eased earlier this year, officials in Poland became vocal critics of the financial obligations laid down by Pfizer’s large vaccine supply pact with the European Union. | As the pandemic eased earlier this year, officials in Poland became vocal critics of the financial obligations laid down by Pfizer’s large vaccine supply pact with the European Union.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Japan approves Daiichi Sankyo’s Covid-19 booster vaccine

Pharmaceutical Technology

Japan’s MHLW has granted approval for Daiichi Sankyo’s Omicron XBB.1.5-adapted monovalent mRNA vaccine as a booster for Covid-19.

article thumbnail

Gilead cuts 7% of staff at Kite Pharma unit as 'refreshed business strategy' introduced

Fierce Pharma

Gilead Sciences' Kite Pharma cell therapy unit is undergoing a business review that will result in layoffs to about 7% of the organization’s workforce. | Gilead’s Kite Pharma cell therapy unit is undergoing a business review that will result in layoffs to about 7% of the organization’s workforce. In a letter sent to staff this week that was obtained by Fierce Biotech, Kite Pharma Executive Vice President Cindy Perettie previewed a “refreshed business strategy” that would better align the un

132
132
article thumbnail

Clinical trial reveals positive results for treating children with rare gliomas

Pharma Times

Tafinlar and Mekinist led to a 56% overall response rate in children with BM-HGG - News - PharmaTimes

article thumbnail

CTO Europe 2023: Cancer clinical trials shift as sector goes digital

Pharmaceutical Technology

Opening the first day of the CTO Europe conference, experts set their sights on the impact of digital technologies on oncology trials.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Novartis dials up midterm sales projection, fleshes out Kisqali's $7B-plus goal

Fierce Pharma

Novartis is getting more optimistic about its midterm sales potential, thanks to bullish estimates for some blockbuster drugs. | Novartis is getting more optimistic about its midterm sales potential, thanks to bullish estimates for some blockbuster drugs, including Entresto and Kisqali.

Sales 126
article thumbnail

Bayer’s stock drops to new 18-year low after asundexian trial termination

Pharmaceutical Technology

As per recommendations, Bayer will continue to investigate asundexian in a different Phase III trial with stroke patients.

Trials 130
article thumbnail

After Cyfendus' full approval, Emergent clinches $75M anthrax vaccine supply pact in US

Fierce Pharma

Armed with a full FDA approval after four years supplying its anthrax vaccine under a pre-emergency use authorization, Emergent BioSolutions is expanding its countermeasure supply pact with the Uni | Armed with a full FDA approval after four years supplying its anthrax vaccine under a pre-emergency use authorization, Emergent BioSolutions is expanding its countermeasure supply pact with the United States.

article thumbnail

Boehringer to leverage IBM’s technologies for antibody discovery 

Pharmaceutical Technology

Boehringer Ingelheim has entered an agreement with IBM to leverage the latter’s foundation model technologies for antibody discovery.

Antibody 130
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

AI-powered ‘MesoGraph’ tool could help clinicians diagnose cancer

Pharma Times

Around 3,000 new cases of mesothelioma are diagnosed in the US every year - News - PharmaTimes

120
120
article thumbnail

FDA grants orphan drug status for Arcturus’ cystic fibrosis therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted orphan drug designation for Arcturus Therapeutics’ ARCT-032 for cystic fibrosis.

Drugs 130
article thumbnail

Putting patients at the centre of innovation starts with clinical trial access

pharmaphorum

Putting patients at the centre of innovation starts with clinical trial access Mike.

article thumbnail

Dermavant CEO draws Botox comparison to instill Vtama confidence amid slow psoriasis uptake

Fierce Pharma

Dermavant CEO Todd Zavodnick isn’t concerned with the slow uptake of the hyped plaque psoriasis drug Vtama. He points to another breakthrough treatment which took a while to catch on: Botox. | Dermavant CEO Todd Zavodnick isn’t concerned with the slow uptake of hyped plaque psoriasis drug Vtama. He points to another breakthrough treatment which took a while to catch on—Botox.

Botox 111
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Veeva Commercial Summit '23: The power of connectivity

pharmaphorum

Veeva Commercial Summit '23: The power of connectivity Mike.

116
116
article thumbnail

Biden looks to broaden HHS powers to bolster domestic drug manufacturing

Fierce Pharma

As drug shortages mount in the U.S. with little relief in sight, President Joe Biden has rolled out a slew of efforts to bolster the nation’s supply chains. | Monday, during the first meeting of the new White House Council on Supply Chain Resilience, President Biden unveiled nearly 30 actions to bolster production networks across industries. Among those actions, Biden intends to leverage the Defense Production Act (DPA) to make more essential medicines at home and thwart future drug shortages.

article thumbnail

Reducing the stigma attached to psychedelics

pharmaphorum

Reducing the stigma attached to psychedelics Mike.

116
116
article thumbnail

How Drug Prices Differ in the U.S. Versus Other Countries

BioSpace

The United States’ relatively high costs have become a political issue on both sides of the aisle. Here’s how international pharmaceutical prices stack up.

Drugs 106
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.